The only way I can parse that sensibly is as follows: for sites that are called as heterozygous in both the Ion Torrent and SOLiD data, the "validation rate" is the proportion where the same two alleles are present. In cases where both datasets call the same type of SNP (heterozygote or homozygous variant) the proportion for which the genotype call is the same Yet the paper appears to cite a "validation rate" for the SNPs called by the Ion Torrent that is implausibly high: So, the authors have two separate low-coverage genomes, both of which would be expected to be missing plenty of SNPs - that means we would expect to see plenty of sites that differ between the two sequences (reflecting changes that by chance were detected by one platform but missed by the other).
(The higher depth of the SOLiD sequencing understates the far higher yield from that platform compared to Ion Torrent for this paper the authors ran over 1,000 chips on the Ion Torrent, whereas the SOLiD coverage was presumably achieved in a single run.) 15x coverage isn't much better than 10x, so the SOLiD sequence would be expected to be missing plenty of heterozygous sites as well. The authors attempted to explicitly estimate their error rate by sequencing Moore's genome a second time using an independent technology: in this case, Life Technologies' SOLiD platform, to a total coverage of around 15x. So how accurate is the genome sequence, really?
Refreshingly, the paper refers to Moore by name, which is a pleasant change from the rather affected pseudo-anonymity of other published genomes (e.g. There's some pleasing symmetry here: Moore's Law is frequently cited in the context of the massive decline in the costs of DNA sequencing in addition, the Ion Torrent technology is based on the same kind of semiconductor technology pioneered by Moore. The genome in question is that of Intel co-founder Gordon Moore, the eponymous originator of Moore's Law. The paper jumps the new platform through the standard hoops: some basic kicking-the-wheels, a test run on three bacterial genomes ( Vibrio fisheri, Escherichia coli, and Rhodopseudomanas palustris), and then the traditional main event: the sequencing of a complete human genome. There's no question the high-impact publication is a massive boost for the young platform, now nestled within the embrace of the giant Life Technologies (who acquired the startup for a surprisingly large price last August) and bracing for the impending launch of its most serious competitor, Illumina's MiSeq. New sequencing technology Ion Torrent has made a splash with a paper in today's issue of Nature.
0 kommentar(er)
